TL02-59

• Description :

  TL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an IC50 of 0.03 nM. TL02-59 inhibits Lyn and Hck with IC50s of 0.1 nM and 160 nM, respectively. TL02-59 potently suppresses acute myelogenous leukemia (AML) cell growth[1].

• CAS Number :

  [1315330-17-6]

• UNSPSC :

  12352005

• Target :

  Apoptosis; Src

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/tl02-59.html

• Purity :

  99.84

• Solubility :

  DMSO : 100 mg/mL (ultrasonic; warming; heat to 80°C)

• Smiles :

  O=C(NC1=CC=C(CN2CCN(CC)CC2)C(C(F)(F)F)=C1)C3=CC=C(C)C(OC4=C5C=C(OC)C(OC)=CC5=NC=N4)=C3

• Molecular Formula :

  C32H34F3N5O4

• Molecular Weight :

  609.64

• References & Citations :

  [1]Weir MC, et al. Selective Inhibition of the Myeloid Src-Family Kinase Fgr Potently Suppresses AML Cell Growth in Vitro and in Vivo. ACS Chem Biol. 2018 Jun 15;13 (6) :1551-1559.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported